Get the Daily Brief
Latest Biotech News
Takara Bio and Resistomap expand high-throughput AMR surveillance platform
Takara Bio and Resistomap said they are strengthening their partnership to deliver a high-throughput antimicrobial resistance (AMR) surveillance workflow built for environmental sampling. The...
Revolution Medicines advances RAS inhibitor daraxonrasib after Phase 3 pancreatic cancer win
Revolution Medicines’ RAS-targeting daraxonrasib moved closer to a pivotal oncology milestone after Phase 3 results in metastatic pancreatic ductal adenocarcinoma. The company reported that...
Kailera’s record $625M IPO funds obesity pipeline
Kailera Therapeutics priced a $625 million initial public offering, marking one of the largest biotech IPOs on record and positioning the company to fund its obesity pipeline. The offering capital...
Neomorph lands $100M Series B for ARNT molecular glue degrader in ccRCC
Neomorph secured a $100 million Series B to advance its oral molecular glue degrader NEO-811 through clinical development. The financing, led by Deerfield Management with participation from...
AACR MRD data highlight ppmSeq ultra-sensitive ctDNA detection approach
Ultima Genomics presented early TRACERx minimal residual disease (MRD) results at AACR emphasizing ppmSeq’s ultra-sensitive circulating tumor DNA (ctDNA) detection. The company described data from...
Roche to buy Saga Diagnostics to expand Foundation Medicine’s MRD toolkit
Roche will acquire Saga Diagnostics via its Foundation Medicine unit in a deal valued at up to $595 million to expand cancer MRD testing. Foundation Medicine says the transaction will bring Saga’s...
Storm Therapeutics raises $56M Series C to fund STC-15 Phase 2 sarcoma trial
Storm Therapeutics closed a $56 million Series C financing to support Phase II development of STC-15, an RNA modification targeting program in sarcoma. The company said it has already treated the...
FDA priority review granted for Merck-Daiichi B7-H3 ADC ifinatamab deruxtecan
The FDA granted priority review to Daiichi Sankyo and Merck’s ifinatamab deruxtecan B7-H3 antibody-drug conjugate. The agency’s decision applies to a BLA seeking treatment for patients with...
Lilly reports positive cardiovascular safety and efficacy in Phase 3 for oral obesity pill Foundayo (orforglipron)
Eli Lilly reported positive Phase 3 results for Foundayo (orforglipron) in a cardiovascular outcomes trial in adults with type 2 diabetes and obesity or overweight. The company said the study met...
Grifols wins FDA approval for Procleix malaria risk screening assay
Grifols said the FDA approved its automated Procleix Plasmodium assay used with the Procleix Panther system to screen blood donors for malaria risk. The nucleic-acid-based test is intended to...
Obesity drugs expand amid FDA safety scrutiny
Eli Lilly’s oral obesity drug Foundayo (orforglipron) cleared an important cardiovascular safety milestone in people with diabetes, meeting the main goal of non-inferiority to insulin glargine for...
Biotech IPO funding benchmark rises with Kailera’s upsized deal
Kailera Therapeutics priced a $625 million offering, a potential benchmark for biotech IPOs, to fund its obesity pipeline. The company’s larger-than-expected raise underscores investor appetite...
RNA epigenetic therapy moves into Phase 2 for sarcoma
Storm Therapeutics closed a $56 million Series C to drive STC-15 into Phase 2 testing across selected sarcoma indications. The RNA-modifying enzyme inhibitor targets METTL3, aiming to disrupt...
FDA priority review advances next B7-H3 ADC in small-cell lung cancer
The FDA accepted and granted priority review to Daiichi Sankyo and Merck’s ifinatamab deruxtecan for advanced extensive-stage small-cell lung cancer. The drug is a B7-H3-directed antibody-drug...
Roche restarts Elevidys Phase 3 to seek revised European approval path
Roche will run a new global Phase 3 trial for Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy Elevidys as it seeks a path to approval in Europe. This follows a negative European...
Foundation Medicine to buy Saga Diagnostics’ MRD platform for up to $595M
Roche subsidiary Foundation Medicine agreed to acquire Saga Diagnostics for up to $595 million to expand its cancer molecular residual disease (MRD) testing portfolio. The deal adds Saga’s...
Revolution Medicines delivers RAS inhibitor advance in metastatic pancreatic cancer
Revolution Medicines priced major concurrent offerings totaling $2 billion shortly after releasing top-line Phase 3 results for daraxonrasib (RMC-6236) in metastatic pancreatic ductal...
Gene therapy rights reshuffle as MeiraGTx buys back failed J&J eye asset
MeiraGTx and Johnson & Johnson completed a buyback arrangement in which J&J handed back rights to the failed eye disease gene therapy bota-vec (botaretigene sparoparvovec) for $25 million upfront....
Biotech financing scale-up continues with Terremoto’s $108M Series C
Terremoto Biosciences raised $108 million in a Series C to advance small-molecule drug programs targeting AKT. The company said funding supports first-in-human testing for its next-generation...
Cell and gene therapy economics spotlight as iPSC manufacturing cuts NK COGS up to 95%
A new cost analysis highlights that manufacturing natural killer cell therapies using induced pluripotent stem cells (iPSCs) can reduce cost of goods sold dramatically versus traditional...